Karyopharm Therapeutics Inc. KPTI

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $146.07M, +0.6% YoY · Filed Feb 13, 2026

Karyopharm Therapeutics Inc. (KPTI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $146.1 million and a net loss of $196.0 million. Free cash flow was -$75.4 million. As of Jun 30, 2026 it held $65.1 million in cash and investments and $6.3 million in total debt.

Revenue (TTM)
$146.62M
+6.8% vs year-ago TTM
Net income (TTM)
$-224.74M
-81.9% vs year-ago TTM
Operating cash flow (TTM)
$-65.35M
+36.5% vs year-ago TTM
Free cash flow
$-75.37M
+40.9% vs prior year
EPS (TTM)
$-11,634.39
+20.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
18.34M
-85.5% vs prior year
Net cash
$58.85M
as of Jun 30, 2026
Operating margin
-56.2%
FY 2026

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KPTI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Newton, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1503802

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$146.1M
$145.2M
$146.0M
$157.1M
$209.8M
Operating income
-$90.7M
-$119.4M
-$129.5M
-$142.2M
-$98.3M
Net income
-$196.0M
-$76.4M
-$143.1M
-$165.3M
-$124.1M
Diluted EPS
-$17.93
-$14.00
-$18.79
-$2.02
—
Operating cash flow
-$75.4M
-$127.5M
-$92.7M
-$149.6M
-$107.1M
Free cash flow
-$75.4M
-$127.6M
-$92.7M
-$149.7M
-$107.3M
Total assets
$108.4M
$164.4M
$240.4M
$358.2M
$305.3M
Total liabilities
$401.3M
$350.4M
$376.6M
$374.8M
$385.0M
Stockholders' equity
-$292.9M
-$186.0M
-$136.2M
-$16.7M
-$79.7M
Cash and investments
$63.7M
$108.7M
$191.4M
$278.0M
$228.6M
Total debt
$6.7M
$7.2M
$6.1M
$9.0M
$180.6M

Recent SEC filings

Form Description Filed Period
8-K Current report
Listing notice
 Nov 5, 2026 Nov 4, 2026
8-K Current report
Material agreement, Bankruptcy, New debt, Regulation FD disclosure, Other events
 Nov 3, 2026 Nov 2, 2026
8-K Current report
Regulation FD disclosure
 Nov 2, 2026 Nov 2, 2026
8-K Current report
Other events
 Oct 22, 2026 Oct 22, 2026
8-K Current report
Other events
 Oct 14, 2026 Oct 13, 2026
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
 Sep 18, 2026 Sep 17, 2026

All 1001 Karyopharm Therapeutics Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.